ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Advances in targeted and cellular therapies for relapsed/refractory mantle cell lymphoma: immunotherapeutic strategies and challenges.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mantle cell lymphoma is an aggressive, heterogeneous B-cell malignancy characterized by frequent relapse, therapeutic resistance, and poor long-term survival in advanced disease. Recent advances in targeted therapy, cellular immunotherapy, and molecular profiling have transformed management. This review summarizes emerging strategies, resistance mechanisms, and translational approaches, emphasizing Bruton tyrosine kinase (BTK) inhibitors, CAR T-cell therapy, bispecific antibodies, SOX11-directed therapy, venetoclax regimens, and precision medicine. A comprehensive narrative review analyzed recent preclinical studies, clinical trials, translational research, and real-world evidence on treatment and resistance biology, focusing on targeted therapies, immunotherapy, molecular biomarkers, and cellular engineering. Therapeutic advances have improved outcomes in relapsed/refractory disease: covalent and noncovalent BTK inhibitors, CAR T-cell therapy, bispecific antibodies, and venetoclax combinations demonstrate significant antitumor activity. However, resistance driven by clonal evolution, antigen escape, tumor microenvironment remodeling, and drug-tolerant persister cells limits durable remission. SOX11-targeted approaches, gene-editing technologies, and measurable residual disease monitoring offer translational promise. Molecular profiling and immunotherapeutics are reshaping personalized management. Combination therapies and biomarker-guided selection may overcome resistance and enhance survival, though treatment toxicity, limited accessibility, and high costs pose challenges. Targeted and cellular therapies are redefining paradigms; precision medicine, resistance-directed strategies, and immunotherapeutic combinations could improve long-term control. This review uniquely integrates evidence on resistance biology, SOX11 therapy, CAR T-cell failure mechanisms, and precision strategies. Future studies should prioritize biomarker-driven approaches, CAR T-cell optimization, safer agents, and accessible treatments for refractory cases.
Indexed as
Identifiers
42340653What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.